BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
Prnewswire·2025-10-14 20:00
, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research. A single-dose of its immunocontraceptive vaccine SpayVacâ"¢ vaccine ("SpayVac") significantly reduced fertility to 11% in vaccinated deer compared to a fertility rate of 86% in ...